Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Sjoukje F. Oosting"'
Autor:
Sjoukje F. Oosting, Robert I. Haddad
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Treating head and neck cancer patients with systemic therapy is challenging because of tumor related, patient related and treatment related factors. In this review, we aim to summarize the current standard of care in the curative and palliative setti
Externí odkaz:
https://doaj.org/article/b33acc77a17341a5b9f64781afef264f
Autor:
Debbie van Baarle, Nynke Y. Rots, Mathilda Jalving, Christian U. Blank, Elisabeth G.E. de Vries, Guus F. Rimmelzwaan, Tatjana T Westphal, Cecile A C M van Els, Anne-Marie C. Dingemans, John B. A. G. Haanen, T. Jeroen N. Hiltermann, Egbert F. Smit, Rudolf S N Fehrmann, Arkajyoti Bhattacharya, Rob van Binnendijk, Astrid A M van der Veldt, Gerco den Hartog, Anke Huckriede, Pia Kvistborg, Corine H. GeurtsvanKessel, Sjoukje F. Oosting, Marion Koopmans, Marieke van der Heiden
Publikováno v:
Lancet Oncology, 22(12), 1681-1691. ELSEVIER SCIENCE INC
The Lancet Oncology, 22(12), 1681-1691. Lancet Publishing Group
The Lancet. Oncology
The Lancet Oncology, 22(12), 1681-1691. Lancet Publishing Group
The Lancet. Oncology
BACKGROUND: Patients with cancer have an increased risk of complications from SARS-CoV-2 infection. Vaccination to prevent COVID-19 is recommended, but data on the immunogenicity and safety of COVID-19 vaccines for patients with solid tumours receivi
Autor:
Sjoukje F Oosting, Astrid A M van der Veldt, Rudolf S N Fehrmann, Corine H GeurtsvanKessel, Rob S van Binnendijk, Anne-Marie C Dingemans, Egbert F Smit, T Jeroen N Hiltermann, Gerco den Hartog, Mathilda Jalving, Tatjana T Westphal, Arkajyoti Bhattacharya, Faye de Wilt, Annemarie Boerma, Lisanne van Zijl, Guus F Rimmelzwaan, Pia Kvistborg, Cecile A C M van Els, Nynke Y Rots, Debbie van Baarle, John B A G Haanen, Elisabeth G E de Vries
Publikováno v:
The Lancet Oncology, 23(7), 833-835. Lancet Publishing Group
Lancet Oncology, 23(7), 833-835. ELSEVIER SCIENCE INC
Oosting, S F, van der Veldt, A A M, Fehrmann, R S N, GeurtsvanKessel, C H, van Binnendijk, R S, Dingemans, A-M C, Smit, E F, Hiltermann, T J N, den Hartog, G, Jalving, M, Westphal, T T, Bhattacharya, A, de Wilt, F, Boerma, A, van Zijl, L, Rimmelzwaan, G F, Kvistborg, P, van Els, C A C M, Rots, N Y, van Baarle, D, Haanen, J B A G & de Vries, E G E 2022, ' Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours ', The Lancet Oncology, vol. 23, no. 7, pp. 833-835 . https://doi.org/10.1016/S1470-2045(22)00203-0
Lancet Oncology, 23(7), 833-835. ELSEVIER SCIENCE INC
Oosting, S F, van der Veldt, A A M, Fehrmann, R S N, GeurtsvanKessel, C H, van Binnendijk, R S, Dingemans, A-M C, Smit, E F, Hiltermann, T J N, den Hartog, G, Jalving, M, Westphal, T T, Bhattacharya, A, de Wilt, F, Boerma, A, van Zijl, L, Rimmelzwaan, G F, Kvistborg, P, van Els, C A C M, Rots, N Y, van Baarle, D, Haanen, J B A G & de Vries, E G E 2022, ' Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours ', The Lancet Oncology, vol. 23, no. 7, pp. 833-835 . https://doi.org/10.1016/S1470-2045(22)00203-0
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3faeb72ddc1ab94cc99e2975667c2840
https://research.vumc.nl/en/publications/ce00c378-f94b-45ef-b9a7-6ef58bfc57d2
https://research.vumc.nl/en/publications/ce00c378-f94b-45ef-b9a7-6ef58bfc57d2
Autor:
Elisabeth G.E. de Vries, Marjolijn N. Lub-de Hooge, Anthonie J. van der Wekken, Sjoukje F. Oosting, Derk Jan A. de Groot, Adrienne H. Brouwers, Rudolf S N Fehrmann, Pim P. van de Donk, Laura Kist de Ruijter
Publikováno v:
Theranostics
Immune checkpoint inhibitors (ICIs) have substantially changed the field of oncology over the past few years. ICIs offer an alternative treatment strategy by exploiting the patients’ immune system, resulting in a T cell mediated anti-tumor response
Autor:
Pim P van de Donk, Sjoukje F Oosting, Daan G Knapen, Anthonie J van der Wekken, Adrienne H Brouwers, Marjolijn N Lub-de Hooge, Derk-Jan A de Groot, Elisabeth GE de Vries
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e004949
The advent of immune checkpoint inhibitors has reinvigorated the field of immuno-oncology. These monoclonal antibody-based therapies allow the immune system to recognize and eliminate malignant cells. This has resulted in improved survival of patient
Autor:
Franco Nolè, Iwona Skoneczna, Francesco Massari, Sabine de Ducla, Sjoukje F. Oosting, Robert Huddart, Herlinde Dumez, Ernest Choy, Pablo Maroto, Birute Brasiuniene, Daniel Castellano, Cora N. Sternberg, Yohann Loriot, Teresa Alonso Gordoa, Flavia Di Nucci, Andre P. Fay, Karina Vianna, Simon Fear
Publikováno v:
EUROPEAN JOURNAL OF CANCER
r-IIB SANT PAU: Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Institut dInvestigació Biomèdica Sant Pau (IIB Sant Pau)
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
European Journal of Cancer, 138, 202-211. ELSEVIER SCI LTD
r-IIB SANT PAU: Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Institut dInvestigació Biomèdica Sant Pau (IIB Sant Pau)
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
European Journal of Cancer, 138, 202-211. ELSEVIER SCI LTD
Aim: Patients with pre-existing autoimmune disease (AID) are typically excluded from clinical trials of immune checkpoint inhibitors, and there are limited data on outcomes in this population. The single-arm international SAUL study of atezolizumab e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ca329aacc3d0499c2cc1da1bda62b62
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1357
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1357
Autor:
Shanhong Guan, Sophia Randolph, Feng Jin, Ezra E.W. Cohen, Kevin J. Harrington, Katherine Ruffner, Jean-Pascal Machiels, Jong Chul Park, Sjoukje F. Oosting, Alison Forgie, Philip Fanning, Tim Welliver, Jaume Pons, Bhumsuk Keam
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A469-A469
BackgroundBoth innate and adaptive immune responses are important components of anticancer immunity. CD47 is a marker of self that interacts with SIRPα on myeloid immune cells, inhibiting their function. CD47 is upregulated by tumors to evade immune
Autor:
Shanhong Guan, Feng Jin, Beatriz Cirauqui, Sophia Randolph, Bhumsuk Keam, Alison Forgie, Philip Fanning, Katherine Ruffner, Jaume Pons, Tim Welliver, Sjoukje F. Oosting, Ezra E.W. Cohen, Jean-Pascal Machiels, Kevin J. Harrington
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundAnticancer immunity relies on the release of tumor antigens and subsequent activation of the innate and adaptive immune systems. After cytotoxic chemotherapy induces neoantigen release, myeloid checkpoint inhibitors can help potentiate inna
Autor:
Thijo J N Hiltermann, T. Westphal, Nynke Y. Rots, Christian U. Blank, G. den Hartog, Marion Koopmans, Mathilde Jalving, Egbert F. Smit, A.A.M. Van der Veldt, M. van der Heiden, Sjoukje F. Oosting, Anne Marie C. Dingemans, J.B.A.G. Haanen, C. A. van Els, R van Binnendijk, A. Battacharya, D. van Baarle, Rudolf S N Fehrmann, E.G.E. de Vries, Corine H. GeurtsvanKessel
Publikováno v:
Annals of Oncology
Background: Patients with cancer have an increased risk of complications from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Vaccination is recommended, but the impact of chemotherapy and immunotherapy on immunogenicity and
Autor:
de Igle Jan Jong, Geke A. P. Hospers, Anna M. Leliveld, Jourik A. Gietema, E.G.E. de Vries, Sjoukje F. Oosting, R R H van den Brom, van Suzanne Es
Publikováno v:
Cancer Treatment Reviews. 46:63-72
The number of elderly patients with renal cell carcinoma is rising. Elderly patients differ from their younger counterparts in, among others, higher incidence of comorbidity and reduced organ function. Age influences outcome of surgery, and therefore